Picture of Connect Biopharma Holdings logo

CNTB Connect Biopharma Holdings Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro Cap

Momentum

Relative Strength (%)
1m-3.1%
3m-44.18%
6m-18.78%
1yr-81.82%
Volume Change (%)
10d/3m-85.63%
Price vs... (%)
52w High-88.19%
50d MA-18.17%
200d MA-53.3%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-36.27%
Return on Equity-367.66%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202231st Dec 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Connect Biopharma Holdings EPS forecast chart

Profile Summary

Connect Biopharma Holdings Ltd is a holding company mainly engaged in the development of clinical-stage biopharmaceutical therapies for the treatment of T cell-driven inflammatory diseases. Its product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha, or IL-4Ra, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis (AD), and asthma. It is also developing CBP-307, a modulator of a T cell receptor known as sphingosine 1-phosphate receptor 1, (S1P1), for the treatment of inflammatory bowel disease (IBD). The Company mainly conducts its businesses in the China market.

Directors

    Last Annual
    December 31st, 2021
    Last Interim
    January 1st, 1970
    Incorporated
    November 23rd, 2015
    Public Since
    March 19th, 2021
    No. of Employees
    108
    Sector
    Biotechnology & Medical Research
    Industry
    Healthcare
    Exchange
    us flag iconNASDAQ Global Market
    Shares in Issue
    57,483,410
    Blurred out image of a map
    Address
    East R&D Building, SUZHOU, 214500
    Web
    https://www.connectbiopharm.com
    Phone
    +86 51253577866
    Contact
    David Carey
    Auditors
    PricewaterhouseCoopers Zhong Tian LLP

    CNTB Share Price Performance

    Upcoming Events for CNTB

    Similar to CNTB

    Picture of 89bio logo

    89bio

    us flag iconNASDAQ Global Market

    Picture of AcelRx Pharmaceuticals logo

    AcelRx Pharmaceuticals

    us flag iconNASDAQ Global Market

    Picture of AC Immune SA logo

    AC Immune SA

    us flag iconNASDAQ Global Market

    Picture of Acrivon Therapeutics logo

    Acrivon Therapeutics

    us flag iconNASDAQ Global Market

    Picture of Adagene logo

    Adagene

    us flag iconNASDAQ Global Market

    FAQ

    Or unlock with your email

    Or unlock with your email